CRSP · CRISPR Therapeutics AG

Track CRSP — free

$58.19 +0.85 (+1.48%)

Russell 2000 member Rebalance outlook locked

Market Cap

$5.45B

96.69M

Volume · Oct 5 1.7M Avg daily vol (3M) 1.58M

Up next

Latest filing: 10-Q

filed Aug 3, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$13.39M

Trailing 12 months

Net income (TTM)

−$451.14M

Trailing 12 months

Revenue growth YoY

+1,041.4%

Year over year

Operating margin

-3,990.0%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-6.8%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$1.78B

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+10.8%

Year over year · more shares

Price change (1Y)

-23.9%

Trailing year

Short interest

19.7%

Latest settlement · 16.5 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Buy Momentum Strong Sentiment Neutral Fundamentals Fair Quant / Vol Very High

Market backdrop VIX 15.5 · calm Equity put/call 0.59

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +8%

above

Price vs 50-day avg +5%

above

RSI (14) 56

neutral

MACD trend Positive

52-week position 40%

mid-range

Momentum

relative strength

Strong

1-month return +3%

trailing

6-month return +1%

trailing

YTD return +9%

this year

Relative strength −11%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $55 › 200d $53 — 50d above 200d

Institutional flow Accumulating

4 of 530 funds reported for Sep 30 · net +603 sh shares

Insider flow Distributing

Net -$780.9K over 90 days · 100% sells

Short interest Rising

19.72% of float · ▲ +1.6% MoM · 16.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

530 holders — near 3-yr high, broad support

Squeeze score 80

high risk · 0–100

Fundamentals

Fair

Revenue growth +9170%

Y/Y

EPS growth −49%

Y/Y

Free cash flow $-345.9M

Balance sheet $347.6M

net cash

Quant / Vol

risk profile

Very High

Volatility 59%

annualized · 1-yr

Max drawdown −42%

past year

ATR 4.9%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Prior guidance period ended · from the 8-K filed Nov 10, 2025

Total CASGEVY revenue · this year (2025) at least $100M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

0 · 3 · 3

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+8% Bullish

Price vs 50-day avg

+5% Bullish

RSI (14)

56 Neutral

MACD trend

Positive Bullish

52-week position

40% Neutral

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $55 › 200d $53 — 50d above 200d

Institutional flow Accumulating

4 of 530 funds reported for Sep 30 · net +603 sh shares

Insider flow Distributing

Net -$780.9K over 90 days · 100% sells

Short interest Rising

19.72% of float · ▲ +1.6% MoM · 16.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

530 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $44 Now $57 · 40% Range high $77

vs 200-day avg +8% vs 50-day avg +5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
CRSP CRISPR Therapeutics AG this stock	$5.45B	+9.3%	+9169.8%	—	19.7%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.37B	+11.1%	+46.2%	30.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$81.13B	-5.9%	+20.8%	19.5	2.5%
MRNA Moderna, Inc.	$79.40B	+589.1%	+4.3%	—	8.2%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

530

% held: 81.5%
Reported: 4 of 530
Top holder: ARK Investment Management…

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Rising

Shares short

19.1M

Days to cover: 16.5d
Change: +301.1K sh

View

Short Volume

Short vol %

65%

As of: Oct 5, 2026

Short Total

View

Fails to Deliver

FTD shares

216

Value: $11.2K
As of: Sep 14, 2026

View

Off-Exchange

Off-exchange %

44.1%

Week of: Aug 31, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$780.9K

Buyers / Sellers: 0 / 1

Buyers Sellers

View

Congressional Trades Sell

Member

Thomas Suozzi

Amount: $50.0K–$100.0K
Traded: Sep 20, 2021

View

Financials

Revenue (FY)

$3.5M

Net income (FY): $-581.6M
EPS diluted: $-6.47

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 3, 2026
This year: 12

View

Proposed Sales

Value

$626.5K

Shares: 10.4K
Filed: Sep 22, 2026

View

Exempt Offerings

Offering

$1.0M

Filed: Apr 10, 2020

View

Earnings & Events

Webcasts

Last webcast

Jun 9, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
CRSP	+6.0%	+2.8%	+0.8%	+3.7%	+9.3%
SPY	+1.2%	+0.6%	+11.6%	+1.6%	+13.6%
vs SPY	+4.8%	+2.2%	-10.7%	+2.1%	-4.3%

Key facts CIK 1674416 CUSIP H17182108 13F (30d) 14 filings 10 filers Visit website Investor relations

CRSP · CRISPR Therapeutics AG

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance